ATE491448T1 - Verfahren zur herstellung eines krebsimpfstoffs - Google Patents

Verfahren zur herstellung eines krebsimpfstoffs

Info

Publication number
ATE491448T1
ATE491448T1 AT07250445T AT07250445T ATE491448T1 AT E491448 T1 ATE491448 T1 AT E491448T1 AT 07250445 T AT07250445 T AT 07250445T AT 07250445 T AT07250445 T AT 07250445T AT E491448 T1 ATE491448 T1 AT E491448T1
Authority
AT
Austria
Prior art keywords
dendritic cells
producing
cancer
tumour cell
cancer vaccine
Prior art date
Application number
AT07250445T
Other languages
English (en)
Inventor
Tan Sri Datuk Yusof Basiron
Hafid Sitti Rahma Abdul
Kanga Rani Selvaduray
Kalanithi Nesaretnam
Original Assignee
Malaysian Palm Oil Board
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Malaysian Palm Oil Board filed Critical Malaysian Palm Oil Board
Application granted granted Critical
Publication of ATE491448T1 publication Critical patent/ATE491448T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT07250445T 2006-02-03 2007-02-02 Verfahren zur herstellung eines krebsimpfstoffs ATE491448T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI20060439A MY160857A (en) 2006-02-03 2006-02-03 A cancer vaccine

Publications (1)

Publication Number Publication Date
ATE491448T1 true ATE491448T1 (de) 2011-01-15

Family

ID=38057880

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07250445T ATE491448T1 (de) 2006-02-03 2007-02-02 Verfahren zur herstellung eines krebsimpfstoffs

Country Status (6)

Country Link
US (1) US7776324B2 (de)
EP (1) EP1815856B1 (de)
JP (1) JP5303113B2 (de)
AT (1) ATE491448T1 (de)
DE (1) DE602007011123D1 (de)
MY (1) MY160857A (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148321A (en) * 2007-10-02 2013-03-29 Malaysian Palm Oil Board Mpob Vitamin e supplementation to tetanus toxoid
CN105861437A (zh) * 2011-10-20 2016-08-17 加利福尼亚干细胞公司 抗原呈递癌症疫苗
CN110885788B (zh) * 2019-12-13 2021-08-17 北京和合医学诊断技术股份有限公司 人肠癌原代细胞、应用和培养方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458585B1 (en) * 1996-08-14 2002-10-01 Nexell Therapeutics Inc. Cytokine-free culture of dendritic cells
DK1305041T3 (da) * 2000-07-28 2006-10-23 Liponova Ag Lægemiddel til immunterapi af maligne tumorer
US7651686B2 (en) * 2001-10-09 2010-01-26 Mayo Foundation For Medical Education And Research Enhancement of immune responses by 4-1bb-binding agents
EP2301356A3 (de) * 2002-12-04 2012-05-30 Baylor Research Institute Schnelles Ein-Schritt-Verfahren zur Erzeugung eines Antigen-geladenen dendritischen Impfstoffs aus Vorläufern
US20060241174A1 (en) * 2005-04-22 2006-10-26 Anne Mueller Vitamin E tocotrienols inhibition of intracellularly obligate pathogen Chlamydia and methods of use

Also Published As

Publication number Publication date
EP1815856A2 (de) 2007-08-08
US20070231351A1 (en) 2007-10-04
US7776324B2 (en) 2010-08-17
JP2007254458A (ja) 2007-10-04
EP1815856B1 (de) 2010-12-15
DE602007011123D1 (de) 2011-01-27
JP5303113B2 (ja) 2013-10-02
EP1815856A3 (de) 2008-05-07
MY160857A (en) 2017-03-31

Similar Documents

Publication Publication Date Title
ATE455463T1 (de) Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren
AU2008298744A8 (en) MiRNA expression in human peripheral blood microvesicles and uses thereof
NO20092522L (no) Sammensetninger og fremgangsmater for a behandle kreft med cupredoxiner og CPG rikt DNA
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
BRPI0814330B8 (pt) métodos e kits cirúrgicos
BRPI0921726B8 (pt) método para preparar uma composição de implante para promover o crescimento ósseo em um mamífero
CR11731A (es) Composiciones y procedimientos para su preparación y uso
EA200801074A1 (ru) Способы получения искусственных гибридных семян
WO2008039874A3 (en) Cancer stem cell antigen vaccines and methods
IN2014MN01981A (de)
UY31816A (es) Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras
WO2010091049A3 (en) Diagnosis and treatment of cancer
CL2008002089A1 (es) Compuesto para la regeneracion de tejidos que comprende al menos una sustancia derivada de sangre y acido hialuronico y/o al menos un compuesto derivado de acido hialuronico; metodo para la prepararcion de dicho compuesto.
EP2560002A3 (de) Verfahren zum Isolieren und/oder Identifizieren mesenchymaler Stammzellen
EA201001749A1 (ru) Способ лечения недифференцированного артрита
GB2497475A (en) Kits, components and methods for tissue reconstruction
MX2010005863A (es) Proceso para reducir los efectos de la enfermedad injerto contra receptor con el uso de celulas t reguladoras cd4+cd25+ expandidas ex vivo.
WO2006093860A3 (en) Method and composition for repairing heart tissue
ATE491448T1 (de) Verfahren zur herstellung eines krebsimpfstoffs
EA201290107A1 (ru) Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапии
MX2007008441A (es) Metodo para producir una vacuna para el tratamiento de cancer.
WO2007137827A8 (de) Isoliertes naturidentisches kollagen
ATE552866T1 (de) Verfahren zur herstellung eines azellulären organischen gewebes
ATE487730T1 (de) Verfahren zur herstellung eines oxaliplatins
BRPI0607882A2 (pt) método e composição para tratamento de diabetes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties